Management of invasive and advanced thyroid cancer

Minerva Endocrinologica

Volumn 34, Issue 1, 2009, Pages 37-55

  Favia, G ^a   Iacobone, M ^a   Zanella, S ^a   Ciarleglio, F A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Diagnosis Thyroid neoplasms; Surgery Thyroidectomy; Thyroid neoplasms

Indexed keywords

(3 IODOBENZYL)GUANIDINE; BLEOMYCIN; CARCINOEMBRYONIC ANTIBODY; COMBRETASTATIN A4; CYCLOPHOSPHAMIDE; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; MANUMYCIN; OCTREOTIDE; PROTEIN TYROSINE KINASE INHIBITOR; RETINOID; RPI 1; UNCLASSIFIED DRUG; VANDETANIB; RADIOACTIVE IODINE;

ADVANCED CANCER; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; DISEASE COURSE; HUMAN; MORBIDITY; NEODYMIUM LASER; NEUROENDOCRINE TUMOR; PROGNOSIS; REVIEW; THYROID CANCER; THYROID MEDULLARY CARCINOMA; ADENOCARCINOMA; CANCER STAGING; CARCINOMA; CHILD; FEMALE; LARYNX; LYMPH NODE METASTASIS; MEDULLARY CARCINOMA; METASTASIS; MULTIMODALITY CANCER THERAPY; NECK MUSCLE; ONCOCYTOMA; PALLIATIVE THERAPY; PAPILLARY CARCINOMA; PATHOLOGY; RECURRENT LARYNGEAL NERVE; THYROID TUMOR; THYROIDECTOMY; TRACHEA;

ADENOCARCINOMA, FOLLICULAR; ADENOMA, OXYPHILIC; CARCINOMA; CARCINOMA, MEDULLARY; CARCINOMA, PAPILLARY; CHILD; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IODINE RADIOISOTOPES; LARYNX; LYMPHATIC METASTASIS; NECK MUSCLES; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; RECURRENT LARYNGEAL NERVE; THYROID NEOPLASMS; THYROIDECTOMY; TRACHEA;

EID: 67650360232     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (174)

1. Breaux Jr GP, Guillamondegui OM. Treatment of locally invasive carcinoma of the thyroid: how radical? Am J Surg 1980;140:514-7.
2. Nishida T, Nakao K, Hamaji M. Differentiated thyroid carcinoma with airway invasion: indication for tracheal resedion based on the extent of cancer invasion. J Thor Cardiovasc Surg 1997;114:84-92. (Pubitemid 27315301)
3. Kebebew E, Clark OH. Differentiated thyroid cancer: "complete" rational approach. World J Surg 2000;24:942-51.
4. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the surveillance, epidemiology and end results (SEER) program 1973-1991. Cancer 1997;79:564-73.
5. Machens A, Hinze R, Lautenschläger C, Thomusch O, Dralle H. Thyroid carcinoma invading the cervicovisceral axis: routes. Thyroid carcinoma invading the cervicovisceral axis: routes of invasion and clinical implications. Surgery 2001;129:23-8.
6. Grillo HC, Suen HC, Mathisen DJ, Wain JC. Resectional management of thyroid carcinoma invading the airway. Ann Thor Surg 1992;54:3-9.
7. Ishihara T, LinksIshihara T, Yamazaki S, Kobayashi K, Inoue H, Fukai S, Ito K, Mimura T. Resection of the trachea infiltrated by thyroid carcinoma. Ann Surg 1982;195:496-500. (Pubitemid 12149264)
8. Kim KH, Sung MW, Chang, KH, Kang BS. Therapeutic dilemmas in the management of thyroid cancer with laryngotracheal involvement. Otolaryngology Head and Neck Surg 2000;122:763-7.
9. McCaffrey JC. Aerodigestive tract invasion by well-differentiated thyroid carcinoma: diagnosis, management, prognosis, and biology.Laryngoscope. 2006;116:1-11.
10. Patel KN, Shaha AR. Locally advanced thyroid cancer. Curr Opin Otolaryngol Head Neck Surg. 2005;13:112-6.
11. Brierley JD, Sang RW. External-beam radiation therapy in the treatment of differentiated thyroid cancer. Sem Surg Onc 1999;16:42-9.
12. Gillenwater AM, Goepfert H. Surgical management of laryngotracheal and esophageal involvement by locally advanced thyroid cancer. Sem Surg Onc 1999;16:19-29. (Pubitemid 28543959)
13. Cody HS, Shah JP. Locally invasive, well-differentiated thyroid cancer. 22 years' experience at Memorial Sloan-Kettering Cancer Center. Am J Surg 1981;142:480-3.
14. McCaffrey TV, Lipton RJ. Thyroid carcinoma invading the upper aerodigestive system. Laryngoscope 1990;100:824-30.
15. Amarasinghe IY, Perera NM, Bahinathan N, Marzook HH, Peiris AK. Review of distribution of nodal disease in differentiated thyroid cancers in an oncosurgical center in Sri Lanka. Ann Surg Oncol 2007;14:1560-4.
16. Tsumori T, Nakao K, Miyata M, Izukura M, Monden Y, Sakurai M et al. Clinicopathologic study of thyroid carcinoma infiltrating the trachea. Cancer 1985;56:2843-8.
17. Grillo HC, Zannini P. Resectional management of airway invasion by thyroid carcinoma. Ann Thorac Surg 1986;42:287-98.
18. Friedman M, Danielzadeh JA, Caldarelli DD. Treatment of patients with carcinoma of the thyroid invading the airway. Archives of Otolaryngology Head Neck Surg 1994;120:1377-81.
19. Sugitani I, Fujimoto Y, Yamamoto N. Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery 2008;143:35-42.
20. Grossman TW, Wilson JF, Toohill RJ. Delayed aerodigestive tract complications following combined therapy for thyroid cancer. Ann Otol Rhinol Laryngol 1985;94:505-8.
21. Talpos GB. Tracheal and laryngeal resections for differentiated thyroid cancer. Am Surg 1999;65:754-9.
22. Yamashita H, Noguchi S, Murakami N, Kawamoto H, Watanabe S. Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma. Cancer 1997;80:2268-72.
23. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986;63:960-7. (Pubitemid 16004302)
24. Pak H, Gourgiotis L, Chang WI, Guthrie LC, Skarulis MC, Reynolds JC et al. Role of metastasedomy in the anagement of thyroid carcinoma: the NIH experience. J Surg Oncol 2003;82:10-8. (Pubitemid 36055486)
25. Larson SM, Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol 2002;37:169-74. (Pubitemid 34764846)
26. van Tol KM, Jager PL, Piers DA, Pruim J, de Vries EG, Dullaart RP et al. Better yield of (18) fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 2002;12:381-7.
27. Goretzki PE, Simon D, Frilling A, Witte J, Reiners C, Grussendorf M et al. Surgical reintervention for differentiated thyroid carcinoma. Br J Surg 1994;90:1009.
28. Park CS, Suh KW, Min JS. Cartilage-shaving procedure for the control of tracheal cartilage invasion by thyroid carcinoma. Head Neck Surg 1993;15:289-91.
29. Gardner RE, Tuttle RM, Burman KD, Haddady S, Truman C, Sparling YH et al. Prognostic importance of vascular invasion in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2000;126:309-12. (Pubitemid 30140383)
30. Niederle B, Hausmaninger C, Kretschmer G, Polterauer P, Neuhold N, Mirza DF et al. Intraatrial extension of thyroid cancer: technique and results of a radical surgical approach. Surgery 1990;108:951-6.
31. Onaran Y, Terzio?lu T, Ouz H, Kapran Y, Tezelman S. Great cervical vein invasion of thyroid carcinoma. Thyroid 1998;8:59-61.
32. Yousem DM, Hatabu H, Hurst RW, Seigerman HM, Montone KT, Weinstein GS et al. Carotid artery invasion by head and neck masses: prediction with MR imaging. Radiology 1995;195:715-20.
33. Thompson NW, Brown J, Orringer M, Sisson J, Nishiyama R. Follicular carcinoma of the thyroid with massive angioinvasion: extension of tumor thrombus to the heart. Surgery 1978;83:451-7. (Pubitemid 8322770)
34. Greene FL, Page DL, Fleming ID. American Joint Committee on Cancer cancer staging manual. 6th edition. New York: Springer Verlag; 2002.
35. Gulcelik MA, Gulcelik NE, Kuru B, Camlibel M, Alagol H. Prognostic factors determining survival in differentiated thyroid cancer. J Surg Oncol 2007;96:598-604. (Pubitemid 350191485)
36. Voutilainen PE, Siironen P, Franssila KO, Sivula A, Haapiainen RK, Haglund CH. AMES, MACIS and TNM prognostic classifications in papillary thyroid carcinoma. Anticancer Res 2003;23:4283-8. (Pubitemid 37474934)
37. National Comprehensive Cancer Network. Thyroid carcinoma. Clinical Practice Guidelines in Oncology, Version 2, 2007 Available at www.nccn.org/. Accessed April 2007.
38. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol 2007;14:730-8.
39. Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 2006;106:524-31. (Pubitemid 43157614)
40. Furlan JC, Bedard YC, Rosen IB. Clinicopathologic significance of histologic vascular invasion in papillary and follicular thyroid carcinomas. J Am Coll Surg 2004;198:341-8.
41. Udelsman R, Chen H. The current management of thyroid cancer. Adv Surg 1999;33:1-27.
42. Kim AW, Maxhimer JB, Quiros RM, Weber K, Prinz RA. Surgical management of well-differentiated thyroid cancer locally invasive to the respiratory trad. Journal of the American College of Surgeons 2005;201:619-27. (Pubitemid 41393086)
43. McCaffrey TV, Bergstralh EJ, Hay ID. Locally invasive papillary thyroid carcinoma: 1940-1990. Head Neck 1994;16:165-72.
44. McCaffrey TV, Lipton RJ Thyroid carcinoma invading the upper aerodigestive system. Laryngoscope 1990;100:824-30.
45. Wilson DB, Staren ED, Prinz RA. Thyroid reoperations: indications and risks. Am J Surg 1998;64:674-8.
46. Sturgeon C, Angelos P. Identification and treatment of aggressive thyroid cancers. Part 2: risk assessment and treatment. Oncology 2006;20:397-404.
47. Samaan NA, Maheshwari YK, Nader S, Hill CS Jr, Schultz PN, Haynie TP et al. Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Clin Endocrinol Metab 1983;56:1131-8. (Pubitemid 13055105)
48. Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL. Radioiodine treatment of metastatic thyroid carcinoma: the royal marsden hospital experience. Br J Radiol 1984;57:323-7.
49. Mazzaferri EL, Massoll N. Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 2002;9:227-47. (Pubitemid 36240764)
50. Breaux Jr GP, Guillamondegui OM. Treatment of locally invasive carcinoma of the thyroid: How radical? Am J Surg 1980;140:514-7.
51. Silliphant WM, Klinck GH, Levitin MS. Thyroid carcinoma and death. A clinicopathological study of 193 autopsies. Cancer 1964;17:513-25.
52. Friedman M, Danielzadeh JA, Caldarelli DD. Treatment of patients with carcinoma of the thyroid invading the airway. Arch Otolaryngol Head Neck Surg 1994;120:1377-81. (Pubitemid 24378581)
53. Nishida T, Nakao K, Hamaji M. Differentiated thyroid carcinoma with airway invasion: indication for tracheal resection based on the extent of cancer invasion. J Thorac Cardiovasc Surg 1997;114:84-92. (Pubitemid 27315301)
54. Bayles SW, Kingdom TT, Carlson GW. Management of thyroid carcinoma invading the aerodigestive tract. Laryngoscope 1998;108:1402-7.
55. Kowalski LP, Filho JG. Results of the treatment of locally invasive thyroid carcinoma. Head Neck 2002;24:340-4.
56. Reeve TS, Delbridge L, Brady P, Crummer P, Smyth C. Secondary thyroidectomy: a twenty-year experience. World J Surg 1988;12:449-53.
57. Chao TC, Jeng LB, Lin JD, Chen MF. Reoperative thyroid surgery. World J Surg 1997;21:644-7.
58. Wilson DB, Staren ED, Prinz RA. Thyroid reoperations: indications and risks. Am J Surg 1998;64:674-8.
59. Dralle H, Brauckhoff M, Machens A, Gimm O. Surgical Management of advanced thyroid cancer invading the aereodigestive tract. In: Clark OH, Duh QY, editors. Textbook of endocrine surgery. Philadelphia, PA: WB Saunders; 1997. p.318-31.
60. Machens A, Hinze R, Lautenschläger C, Thomusch O, Dralle H. Thyroid carcinoma invading the cervicovisceral axis: routes of invasion and clinical implications. Surgery 2001;129:23-8. (Pubitemid 32099253)
61. Machens A, Hinze R, Dralle H. Surgery on the cervicovisceral axis for invasive thyroid cancer. Langenbecks Arch Surg 2001;386:318-23. (Pubitemid 32851796)
62. Machens A, Hinze R, Lautenschläger C, Thomusch O, Dunst J, Dralle H. Extended surgery and early postoperative radiotherapy for undifferentiated thyroid carcinoma. Thyroid 2001;11:373-80. (Pubitemid 32422631)
63. Machens A, Hinze R, Lautenschläger C, Dralle H. Multivariate analysis of clinicopathologic parameters for the insular subtype of differentiated thyroid carcinoma. Arch Surg 2001;136:941-4. (Pubitemid 32729557)
64. Machens A, Dralle H. Mycotic aneurysm of common carotid artery induced by Staphylococcus aureus infection after cervical reoperation. World J Surg 2001;25:1113-6.
65. Shin DH, Mark EJ, Suen HC, Grillo HC. Pathologic staging of papillary carcinoma of the thyroid with airway invasion based on the anatomic manner of extensione to the trachea: a clinicopathologic study based on 22 patients who underwent thyroidectomy and airway resedion. Hum Pathol 1993;24:866.
66. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986;63:960-7.
67. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988;67:501-8.
68. Massin JP, Savoie JC, Garnier H, Guiraudon G, Leger FA, Bacourt F. Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer 1984;53:982-92.
69. Shaha AR, Shah JP, Loree TR. Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg 1997;174:474-6.
70. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 2000;6:469-76.
71. Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 2003;197:191-7.
72. Stojadinovic A, Shoup M, Ghossein RA, Nissan A, Brennan MF, Shah JP, Shaha AR. The role of operations for distantly metastatic well-differentiated thyroid carcinoma. Surgery 2002;131:636-43.
73. Grillo HC, Dignan EF, Miura, Scannell JG. Extensive resection and reconstruction of mediastinal trachea without prosthesis or graft: an anatomical study. J Thorac Cardiovasc Surg 1964;48:741.
74. Salassa JR, Pearson BW, Payne WS. Gross and microscopical blood supply of trachea. Ann Thorac Surg 1977;24:100.
75. Grillo HC, Suen HC, Mathisen DJ, Wain JC. Resectional management of thyroid carcinoma invading the airway. Ann Thorac Surg 1992;54:3.
76. Grillo HC, Mathisen DJ, Wain JC. Laryngotracheal resection and reconstruction for subglottic stenosis. Annthrac Surg 1992;54:54.
77. Grillo HC. Tracheal resection. Arch Otolaryngol 1972;96:31.
78. Montgomery WW. Suprahyoid release for tracheal anastomosis. Arch Otolaryngol 1974;99:255.
79. Marzano LA, Porcelli A. Surgical Management and follow-up of medullary thyroid carcinoma. J Surg Onc 1995;59:162-168.
80. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
81. Kebebew E, Clark OH. Locally advanced differentiated thyroid cancer. Surg Oncol 2003;12:91-9.
82. Dackiw APB, Zeiger M. Extent of surgery for differentiated thyroid cancer. Surg Clin N Am 2004;84:817-32.
83. Lalak NJ, Campbell PR. Infiltrating papillary carcinoma of the thyroid with macroscopic extension into the internal jugular vein. Otolaryngology Head Neck Surg 1997;117:S228-30.
84. Thomas S, Sawhney S, Kapur BM. Case report: bilateral massive internal jugular vein thrombosis in carcinoma of the thyroid: CT evaluation. Clini Radiol 1991;43:433-4.
85. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocr Metab 1995;80:2041-5.
86. Schlumberger M, De Vathaire F, Ceccarelli C, Delisle MJ, Francese C, Couette JE et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996;37:598-605.
87. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocr Metab 1995;80:1488-92.
88. Proye CA, Dromer DH, Carnaille BM, Gontier AJ, Goropoulos A, Carpentier P et al. Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? World J Surg 1992;16:640-5.
89. Do MY, Rhee Y, Kim DJ, Kim CS, Nam KH, Ahn CW et al. Clinical features of bone metastases resulting from thyroid cancer: a review of 28 patients over a 20-year period. Endocr J 2005;52:701-7.
90. Fanchiang JK, Lin JD, Huang MJ, Shih HN. Papillary and follicular thyroid carcinomas with bone metastases: a series of 39 cases during a period of 18 years. Changgeng Yi Xue Za Zhi 1998;21:377-82.
91. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM, Robbins RJ. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 2000;10:261-8.
92. Marcocci C, Pacini F, Elisei RI. Clinical and biologic behavior of bone metastases from differentiated thyroid carcinoma. Surgery 1989;106:960-6.
93. Aguiar PH, Agner C, Tavares FR, Yamaguchi N. Unusual brain metastases from papillary thyroid carcinoma: case report. Neurosurgery 2001;49:1008-13.
94. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997;82:3637-42.
95. Parker LN, Wu SY, Kim DD, Kollin J, Prasasvinichai S. Recurrence of papillary thyroid carcinoma presenting as a focal neurologic deficit. Arch Intern Med 1986;146:1985-7.
96. Datz FL. Cerebral edema following iodine-131 therapy for thyroid carcinoma metastatic to the brain. J Nucl Med 1986;27:637-40.
97. Holmquest DL, Lake P. Sudden hemorrhage in metastatic thyroid carcinoma of the brain during treatment with iodine-131. J Nucl Med 1976;17:307-9.
98. Pazaitou-Panayiotou K, Kaprara A, Chrisoulidou A, Boudina M, Georgiou E, Patakiouta F et al. Cerebellar metastasis as first metastasis from papillary thyroid carcinoma. Endocr J 2005;52:653-7.
99. Cha ST, Jarrahy R, Mathiesen RA, Suh R, Shahinian HK. Cerebellopontine angle metastasis from papillary carcinoma of the thyroid: case report and literature review. Surg Neurol 2000;54:320-6.
100. Ewing J. Neoplastic diseases. 2nd edition. Philadelphia, PA: WB Saunders Co; 1928. p. 952-3.
101. Cooper DS, Schneyer CR. Follicular and hurthle cell carcinoma of the thyroid. Endocr Metab Clin North Am 1990;19:577-91.
102. Hedinger C. Histological typing of thyroid tumours. vol. 7. New York, NY: Springer; 1987.
103. Tollefsen HR, Shah JP, Huvos AG. Hurthle cell carcinoma of the thyroid. Am J Surg 1975;130:390-4.
104. Bondeson L, Bondeson AG, Ljungberg O, Tibblin S. Oxyphil tumors of the thyroid: follow- up of 42 surgical cases. Ann Surg 1981;194:677-80.
105. Watson RG, Brennan MD, Goellner JR, van Heerden JA, McConahey WM, Taylor WF. Invasive hurthle cell carcinoma of the thyroid: natural history and management. Mayo Clin Proc 1984;59:851-5.
106. McLeod MK, Thompson NW. Hurthle cell neoplasms of the thyroid. Otolaryngol Clin North Am 1990;23:441-52.
107. Herrera MF, Hay ID, Wu PS, Goellner JR, Ryan JJ, Ebersold JR et al. Hurthle cell (oxyphilic) papillary thyroid carcinoma: a variant with more aggressive biologic behavior. World J Surg 1992;16:669-74.
108. Gosain AK, Clark OH. Hurthle cell neoplasms. Malignant potential. Arch Surg 1984;119:515-9.
109. Azadian A, Rosen IB, Walfish PG, Asa SL. Management considerations in hurthle cell carcinoma. Surgery 1995;118:711-4.
110. Chen H, Udelsman R. Hurthle cell adenoma and carcinoma. In: Clark OH, Duh QY, editors. Textbook of endocrine surgery. Philadelphia, PA: WB Saunders; 1997. p.101-6.
111. Chen H, Nicol TL, Zeiger MA. Hurthle cell neoplasms of the thyroid: are there factors predictive of malignancy? Ann Surg 1998;227:542-6.
112. Hessel A, Chalian AA, Clayman GL. Surgical management of recurrent thyroid cancer. Neuroimaging Clin N Am 2008;18:517-25.
113. Muzaffar M, Nigar E, Mushtaq S, Mamoon N. The morphological variants of papillary carcinoma of the thyroid: a clinicopathological study - AFIP experience. Armed forces Institute of Pathology. J Pak Med Assoc 1998;48:133-7.
114. Sywak M, Pasieka JL, Ogilvie T. A review of thyroid cancer with intermediate differentiation. J Surg Oncol 2004;86:44-54.
115. Sturgeon C, Angelos P. Identification and treatment of aggressive thyroid cancers. Part 1: subtypes. Oncology 2006;20:253-60.
116. National Cancer Institute, SEER. Incidence: thyroid cancer. Bethesda, MD: National Cancer Institute, SEER; 2004.
117. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995 [see comments]. Cancer 1998; 83:2638-48.
118. Bhattacharyya N. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Head Neck Surg 2003;128:115-23.
119. Modigliani E, Vasen HM, Raue K. Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The euromen study group. J Intern Med 1995;238:363-7.
120. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the surveillance, epidemiology and end results (SEER) program 1973-1991. Cancer 1997;79:564-73.
121. Saad MF, Fritsche Jr HA, Samaan NA. Diagnostic and prognostic values of carcinoembryonic antigen in medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1984;58:889-94.
122. Barbet J, Campion L, Kraeber-Bodere F, Chatal JF, GTE Study Group. Prognostic impact of serum caltitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005;90:6077-84.
123. Giuffrida D, Gharib H. Current diagnosis and management of medullary thyroid carcinoma. Ann Oncol 1998;9:695-701. (Pubitemid 28394153)
124. Chen H, Kunnimalaiyaan M, Van Gompel JJ. Medullary thyroid cancer: the functions of raf- 1 and human achaete-scute homologue-1. Thyroid 2005;15:511-21. (Pubitemid 40993724)
125. Brunt LM, Wells Jr SA. Advances in the diagnosis and treatment of medullary thyroid carcinoma. Surg Clin N Am 1987;67:263-79.
126. van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM. Longterm course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 1990;212:395-400. (Pubitemid 20369771)
127. Chen H, Roberts JR, Ball DW. Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg 1998;227:887-95.
128. Machens A, Gimm O, Ukkat J, Sutter T, Dralle H. Repeat mediastinal lymph-node dissection for palliation in advancedmedullary thyroid carcinoma. Langenbecks Arch Surg 1999;384:271-6. (Pubitemid 29309071)
129. Kebebew E, Clark OH. Medullary thyroid cancer. Curr Treat Op Onc 2000;1:359-67.
130. Lorenz K, Brauckhoff M, Behrmann C. Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery 2005;138:986-93. (Pubitemid 41797336)
131. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FUdacarbazine. The groupe d'etude des tumeurs a calcitonine (GETC). Br J Cancer 1995;71:363-5.
132. Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany- Corone C, Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin- streptozocin and 5 FU-dacarbazine. Groupe d'etude des tumeurs a calcitonine (GETC). Br J Cancer 2000;83:715-8.
133. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocr 2004;61:299-310.
134. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 1994;21:561-81.
135. Troncone L, Rufini V. 131I-MIBG therapy of neural crest tumours (review). Anticancer Res 1997;17:1823-31. (Pubitemid 27263167)
136. Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J et al. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-metaiodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol 2001;55:47-60.
137. Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111in- pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003;44:1-6.
138. Pasieka JL, McEwan AJ, Rorstad O. The palliative role of 131IMIBG and 111In-octreotide therapy in patients with metastatic progressive neuroendocrine neoplasms. Surgery 2004;136:1218-26.
139. Chatal JF, Campion L, Kraeber-Bodere F. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic- antigen radioimmunotherapy: a collaborative study with the French endocrine tumor group. J Clin Onc 2006;24:1705-11.
140. Eng C, Smith DP, Mulligan LM. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994;3:237-41.
141. Grieco M, Santoro M, Berlingieri MT. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-63.
142. Cuccuru G, Lanzi C, Cassinelli G. Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 2004;96:1006-14. (Pubitemid 39162643)
143. Petrangolini G, Cuccuru G, Lanzi C. Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by ret inhibitor RPI. Bioch Pharmacol 2006;72:405-14. (Pubitemid 44061744)
144. Carlomagno F, Vitagliano D, Guida T. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficientlyblocks oncogenic RET kinases. Cancer Res 2002;62:7284-90. (Pubitemid 36025251)
145. Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003;9:1546-56.
146. Kunnimalaiyaan M, Chen H. The raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs 2006;17:139-42.
147. Kunnimalaiyaan M, Ndiaye M, Chen H. Apoptosis mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery 2006;140:1009-15.
148. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006;13:453-64.
149. Junor FJ, Paul J, Reed NS. Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 1992;18:83-8.
150. Tan RK, Finley III RK, Driscoll D, Bakamjian V, Hicks Jr WL, Shedd DP. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995;17:41-7.
151. Kobayashi T, Asakawa H, Umeshita K. Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck 1996;18:36-41. (Pubitemid 26002035)
152. Nilsson O, Lindeberg J, Zedenius J, Ekman E, Tennvall J et al. Anaplastic giant cell carcinoma of the thyroid gland: treatment and survival over a 25-year period. World J Surg 1998;22:725-30.
153. Haigh PI, Ituarte PH, Wu HS. Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001;91:2335-42.
154. Thyroid Carcinoma Task Force. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 2001;7:202-20.
155. Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 2002;86:1848-53.
156. Wong CS, Van Dyk J, Simpson WJ. Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 1991;20:3-9.
157. Wassermann K, Eckel HE, Michel O, Muller RP. Emergency stenting of malignant obstruction of the upper airways: longterm follow-up with two types of silicone prostheses. J Thorac Cardiovasc Surg 1996;112:859-66.
158. Ribechini A, Bottici V, Chella A, Elisei R, Vitti P, Pinchera A et al. Interventional bronchoscopy in the treatment of tracheal obstruction secondary to advanced thyroid cancer. J Endocr Invest 2006;29:131-5.
159. Noppen M, Poppe K, D'Haese J, Meysman M, Velkeniers B, Vincken W. Interventional bronchoscopy for treatment of tracheal obstruction secondary to benign or malignant thyroid disease. Chest 2004;125:723-30.
160. Sugawara L, Arai T, Yamashita T, Yoshida A, Masunaga A, Itoyama S. Expression of multidrug resistance-associated protein (MRP) in anaplastic carcinoma of the thyroid. Cancer Lett 1994;82:185-8. (Pubitemid 24231984)
161. Pan J, Xu G, Yeung SC. Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. J Clin End Met 2001;86:4731-40.
162. Xu G, Pan J, Martin C, Yeung SC. Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocr Metab 2001;86:1769-77.
163. Blagosklonny MV, Giannakakou P, Wojtowicz ML. Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 1998;83:2516-22.
164. Nagayama Y, Yokoi H, Takeda K, Hasegawa M, Nishihara E, Namba H et al. Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo. J Clin Endocrinol Metab 2000;85:4081-6.
165. Lee WW, Lee B, Kim SJ, Jin J, Moon DH, Lee H. Kinetics of iodide uptake and efflux in various human thyroid cancer cells by expressing sodium iodide symporter gene via a recombinant adenovirus. Onc Rep 2003;10:845-9.
166. Furuya F, Shimura H, Miyazaki A. Adenovirus-mediated transfer of thyroid transcription factor-1 induces radioiodide organification and retention in thyroid cancer cells. Endocrinology 2004;145:5397-405. (Pubitemid 39551161)
167. Elisei R, Vivaldi A, Ciampi R. Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic add. J Clin Endocrinol Metab 2006;91:2389-95. (Pubitemid 43855032)
168. Venkataraman GM, Yatin M, Marcinek R, Ain KB. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 1999;84:2449-57.
169. Furuya F, Shimura H, Suzuki H. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thryroperoxidase and thyroglobulin. Endocrinology 2004;145:2865-75. (Pubitemid 38686236)
170. Schmutzler C. Regulation of the sodium/iodide symporter by retinoids - a review. Exp Clin End Diab 2001;109:41-4.
171. Dowlati A, Robertson K, Cooney M. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a singledose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16.
172. Dziba JM, Marcinek R, Venkataraman G, Robinson JA, Ain KB. Combretastatin A4 phosphate has primary antineoplastic activity against human anaplastic thyroid carcinoma cell lines and xenograft tumors. Thyroid 2002;12:1063-70.
173. Franzen A, Heldin NE. BMP-7-induced cell cycle arrest of anaplastic thyroid carcinoma cells via p21(CIP1) and p27(KIP1). Bioch Bioph Res Comm 2001;285:773-81.
174. Kotchetkov R, Cinatl J, Krivtchik AAl. Selective activity of BS-RNase against anaplastic thyroid cancer. Anticancer Res 2001;21:1035-42. (Pubitemid 32494204)